BMY
BUYNeutralComposite
71.60
Technical
88.40
Fundamental
60.40
Rank
—
Price
66.46
Hurst
0.45
As of
Aug 3, 2026
Daily
Bristol-Myers Squibb Company
HealthcareDrug Manufacturers - GeneralBristol-Myers Squibb is a global biopharmaceutical company that discovers, develops, and commercializes medicines across oncology, hematology, immunology, cardiovascular, and neuroscience areas. The company's portfolio includes treatments such as Opdivo for cancer, Eliquis for stroke prevention and blood clots, Revlimid for multiple myeloma, Orencia for rheumatoid arthritis, and various other therapies for conditions including melanoma, leukemia, psoriasis, and schizophrenia. The company distributes its products through wholesalers, pharmacies, hospitals, and government agencies.
Market cap
$127.7B
P/E (trailing)
13.85
P/E (forward)
9.40
PEG ratio
17.32
Dividend yield
403.00%
Beta
0.18
52w range
45.27 – 68.64
Return on equity
+44.01%
Profit margin
+18.47%
Revenue growth
+6.90%
Earnings growth
-2.80%
Price history
1Y: 62.48 (+41.6%) · range 43.65–67.39
Cycle position
52/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 22 · NOT READY · exit proximity 0
Conviction
35/ 100 · maturity 43%
VScore.2231
Buildup.2633
EMA entry setup.3222
Fundamentals.1960
Volume profile
POC
61.84
Price vs POC
+1.0%
Overhead supply
29%
Runway
+0.5%
Value area 55.43–64.81 · 29% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.746 | Oct 30, 2026 |
| trader-sentiment | 0.115 | Oct 30, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +0.59% | +3.08% | 2/20d |
| 40d | +0.59% | +3.08% | 2/40d |